New EndeavorRx® features released as Akili
begins to scale its commercial activities
PureTech Health plc (Nasdaq:PRTC, LSE:PRTC) (“PureTech” or the
“Company”), a clinical-stage biotherapeutics company, today
announced that its Founded Entity, Akili Interactive (“Akili”),
introduced new gaming features and functionalities to its
EndeavorRx® treatment. The new gameplay features are being released
as Akili begins its go-to market approach to bring EndeavorRx to
families and healthcare professionals at scale.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210722005582/en/
PureTech’s Founded Entity, Akili
Interactive, introduced new gaming features and functionalities to
its FDA-cleared EndeavorRx treatment for children with ADHD. The
new gameplay features are being released as Akili begins to scale
its commercial activities. (Graphic: Business Wire)
Akili leveraged its expertise in two disparate industries –
medicine and gaming – to identify opportunities to enhance the
EndeavorRx gameplay experience without changing Akili’s patented
Selective Stimulus Management Engine (SSME™) core technology
designed to improve attention function. The enhancements were based
on the latest trends in video game development and informed by user
insights collected across multiple forums, including playtesting,
workshops, in-depth interviews with patients and caregivers,
surveys, gameplay data and longitudinal research.
The full text of the announcement from Akili is as follows:
Akili Releases New Gameplay Features in the
First and Only FDA-Cleared Video Game Treatment for Children With
ADHD
Akili delivers on commitment to unparalleled
patient experiences with continuous product enhancements
New EndeavorRx features released as Akili
begins to scale its commercial activities
BOSTON, Mass. – July 22, 2021 – Akili Interactive
(“Akili” or “Company”), maker of the first and only prescription
video game treatment, today introduced new gaming features and
functionalities to its EndeavorRx® treatment following its U.S.
Food and Drug Administration (FDA) clearance in June 2020. The new
gameplay features are part of Akili’s commitment to continuous
product iterations to create enjoyable, entertaining patient
experiences and are being released as Akili begins its go-to market
approach to bring EndeavorRx to families and healthcare
professionals at scale. Leveraging insights from caregivers and
patients, Akili game designers and engineers have created
additional gameplay experiences that offer exciting new quests and
increased optionality, including new personalized universes and
character choices to enhance engagement in the prescription digital
therapeutic. Enabled by the adaptive ability of digital
therapeutics and the dynamic nature of video games, these
enhancements evolve the gameplay experience for patients while
preserving the regulated core technology of the product.
Because EndeavorRx is uniquely delivered through a video game, a
number of gameplay components can be enhanced to drive user
engagement and motivation. Akili leveraged its expertise in two
disparate industries – medicine and gaming – to identify
opportunities to enhance the EndeavorRx gameplay experience without
changing Akili’s patented Selective Stimulus Management Engine
(SSME™) core technology designed to improve attention function. The
enhancements were based on the latest trends in video game
development and informed by user insights collected across multiple
forums, including playtesting, workshops, in-depth interviews with
patients and caregivers, surveys, gameplay data and longitudinal
research.
“Rapid product iteration is critical to creating amazing
experiences for patients and delivering on the full promise of
digital therapeutics,” said Carl Gottlieb, Senior Vice President of
Engineering at Akili Interactive. “Since obtaining FDA clearance,
we’ve been listening and learning, and are taking a dynamic
patient-responsive approach to create an amazing experience -- from
the product to the delivery process. Because EndeavorRx is uniquely
delivered through a video game, we have nearly endless
opportunities to enhance the product and evolve it based on user
feedback and gaming trends to drive enjoyment and engagement.”
New features were added to EndeavorRx, with a primary focus on
gameplay progress, increased choice and personalization. The
enhancements provide patients with more strategic challenges and
add complexity to both short-term and long-term goals to drive
motivation. Patients now have more choices during gameplay,
including selecting and unlocking new creatures and costumes,
completing new quests, and building their own universes, which
provide increased optionality and foster longer-term engagement and
interest.
“My son began playing EndeavorRx last year, and these new
features have personalized the game even further to his unique
player level and capabilities,” said Kelcey Sihanourath, whose
12-year-old son has ADHD. “All of the interesting graphics and
worlds he can visit keep him motivated and the gaming experience
fresh and entertaining, despite it being an actual prescription
treatment. For example, I remember he was saving up his rewards for
one particular costume, and was so proud to show it to me once he
had earned enough points. It has been such a rewarding experience
to be able to give my son a treatment in the form of a video game
he’s happy and excited about playing!”
EndeavorRx treatment was granted FDA clearance based on data
from five clinical studies in more than 600 children diagnosed with
ADHD, including a prospective, randomized, controlled study (STARS)
published in The Lancet Digital Health journal, which showed
EndeavorRx improved objective measures of attention in children
with ADHD. In March 2021, data published in Nature Digital Medicine
from a multi-site open-label study (STARS Adjunct) evaluating the
impact of EndeavorRx on symptoms and functional impairments in
children with ADHD demonstrated statistically significant
improvement in all predetermined endpoints of the study, which
included parent and clinician ratings of children’s ADHD symptoms
and related impairments in daily life.
To learn more or download a guide on how to talk to a child’s
doctor about EndeavorRx, please visit EndeavorRx.com.
EndeavorRx® Indication and Overview EndeavorRx is
indicated to improve attention function as measured by
computer-based testing in children ages 8-12 years old with
primarily inattentive or combined-type ADHD, who have a
demonstrated attention issue. Patients who engage with EndeavorRx
demonstrate improvements in a digitally assessed measure Test of
Variables of Attention (TOVA®) of sustained and selective attention
and may not display benefits in typical behavioral symptoms, such
as hyperactivity. EndeavorRx should be considered for use as part
of a therapeutic program that may include clinician-directed
therapy, medication, and/or educational programs, which further
address symptoms of the disorder. EndeavorRx is available by
prescription only. It is not intended to be used as a stand-alone
therapeutic and is not a substitution for a child’s medication.
EndeavorRx is built on the Akili Selective Stimulus Management
Engine (SSME™) core technology, a proprietary technology designed
to target key attentional control systems in the brain. SSME
technology presents specific sensory stimuli and simultaneous motor
challenges designed to target and activate the neural systems that
play a key role in attention function while using adaptive
algorithms to personalize the treatment experience for each
individual patient. This enables second by second monitoring of
patient progress completing the treatment sessions, and
continuously challenges each patient to an optimized level,
encouraging patients to improve their performance. Driven by the
core belief at Akili that effective medicine can also be fun and
engaging, EndeavorRx is delivered through an action video game
experience. The captivating experience of EndeavorRx is designed to
drive engagement and compliance. To learn more about EndeavorRx,
please visit EndeavorRx.com.
About Akili Akili is combining scientific and clinical
rigor with the ingenuity of the tech and entertainment industries
to challenge the status quo of medicine. Akili is pioneering the
development of digital treatments and care solutions to help people
affected by cognitive impairments. Akili’s treatments are designed
to directly activate the networks in the brain responsible for
cognitive function and have been rigorously tested in extensive
clinical studies, including prospective randomized, controlled
trials. Driven by Akili’s belief that effective medicine can also
be fun and engaging, Akili’s treatments are delivered through
captivating action video game experiences. For more information,
please visit AkiliInteractive.com.
Akili, EndeavorRx, and SSME, and any logo(s) for each, are
trademarks or registered trademarks of Akili Interactive Labs, Inc.
Other trademarks are trademarks or registered trademarks of their
respective owners.
About PureTech Health PureTech is a clinical-stage
biotherapeutics company dedicated to discovering, developing and
commercializing highly differentiated medicines for devastating
diseases, including inflammatory, fibrotic and immunological
conditions, intractable cancers, lymphatic and gastrointestinal
diseases and neurological and neuropsychological disorders, among
others. The Company has created a broad and deep pipeline through
the expertise of its experienced research and development team and
its extensive network of scientists, clinicians and industry
leaders. This pipeline, which is being advanced both internally and
through PureTech's Founded Entities, is comprised of 26
therapeutics and therapeutic candidates, including two that have
received FDA clearance and European marketing authorization, as of
the date of PureTech’s most recently filed Annual Report on Form
20-F. All of the underlying programs and platforms that resulted in
this pipeline of therapeutic candidates were initially identified
or discovered and then advanced by the PureTech team through key
validation points based on the Company's unique insights into the
biology of the brain, immune and gut, or BIG, systems and the
interface between those systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements This
press release contains statements that are or may be
forward-looking statements, including statements that relate to the
Akili’s goals with respect to the EndeavorRx gameplay experience,
the company's future prospects, development plans and strategies.
The forward-looking statements are based on current expectations
and are subject to known and unknown risks and uncertainties that
could cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, our expectations regarding the EndeavorRx features and gameplay
enhancements, and those risks and uncertainties described in the
risk factors included in the regulatory filings for PureTech Health
plc. These forward-looking statements are based on assumptions
regarding the present and future business strategies of the company
and the environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210722005582/en/
Investors Allison Mead Talbot +1 617 651 3156
amt@puretechhealth.com
U.S. media Stephanie Simon +1 617 581 9333
stephanie@tenbridgecommunications.com
PureTech Health (NASDAQ:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
PureTech Health (NASDAQ:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024